The global HPV Testing and Pap Test Market was valued at around USD 2.2 Billion in 2021. With a projected CAGR of 19.3% for the next ten years, the market is likely to reach a valuation of approximately USD 15 Billion by the end of 2032.
| Attributes | Details |
|---|---|
| HPV Testing and Pap Test Market Size (2021A) | USD 2.2 Billion |
| Estimated Market Value (2022E) | USD 2.6 Billion |
| Forecasted Market Value (2032) | USD 15 Billion |
| Global Market Growth Rate (2022 to 2032) | 19.3% CAGR |
| United States Forecasted Market Value (2032) | USD 5.9 Billion |
| USA Growth Rate(2022 to 2032) | 20.4% CAGR |
| Key Companies Covered | Abbott Laboratories Qiagen N.V.; Becton Dickinson and Company; Quest Diagnostics Inc.; Hologic Inc.; F. Hoffmann-La Roche; Femasys Inc.; Arbor Vita Corporation; NURX Inc.; Seegene Inc.; Thermo Fisher Scientific. Inc.; bioMérieux SA |
Future Market Insights’ analysis reveals that most of the HPV Testing and Pap Test market revenue are grossed from Pap Tests, which have a predicted CAGR of 16.8% by 2032. Cervical Cancer Screening is the top application of these tests, with a CAGR of 18.4% in the forecast period. HVC and Pap tests are used extensively in Cervical Cancer Screening and awareness drives, government policies, and programs provide a significant demand boost.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global HPV Testing and Pap Test market expanded at a CAGR of 17.2% from 2015 to 2021. The global market is predicted to surge ahead at a CAGR of 19.3% and record sales worth USD 15 Billion by the end of 2032, registering an absolute dollar opportunity of USD 12 Billion from 2022 to 2032.
Cervical cancer is the 4th most common form of cancer amongst women worldwide. In 2020, there were an estimated 604,000 new cases and 342,000 related deaths. Cervical cancer is most treatable and curable if vaccinations are effective and the cancer is detected at an early stage and proper treatment is given promptly.
If detected at an early stage, the 5-year survival rate is very high at around 92%. Even cancers at later stages can be managed with proper treatment and care. The global strategy for cervical cancer elimination, endorsed by the WHO in 2020, aims for 70% of women globally to have undergone testing at regular intervals by 2030.
The policy is based on the idea that implementing this, along with other policies regarding treatment and vaccination could eliminate cervical cancer deaths in a century. According to the WHO, this could prevent around 62 million deaths.
Pap testing, which tests for cell changes that could potentially be or become cervical cancer, and HPV testing, which looks for high-risk HPV are globally recommended. In recent years, demand is increasing due to increased awareness, developments in reducing costs, and government policies and programs.
Principal Consultant
There have been a number of government programs and policies that are boosting the global demand for testing. In the USA, the CDC recommends a Pap test or cytology test once every 3 years for 21-29-year-olds and a pap test every 3 years or an HPV test every 5 years, or a cotest of both Pap and HPV tests every 5 years for those over 30 years.
In China, the All-China Women's Federation and the Ministry of Health launched a dual program for screening cervical and breast cancer in rural women, at 3-year intervals. In Japan, the National Cancer Center recommends screening every 2 years.
Most cities offer free or subsidized options for women of eligible age groups. In South Korea, which has a single-payer public health insurance system, eligible women over 20 years of age are provided a free screening once every 2 years.
Nearly 90% of HPV deaths occurring in 2020, occurred in low and middle-income countries; largely owing to the fact that low-resource areas often do not have the ability to provide regular screening. A commonly used method is Visual Inspection with Acetic Acid or VIA testing which involves a health worker applying dilute acetic acid to the cervix and inspecting it for visual signs of whitening with the naked eye.
This method is used despite lower accuracy in low-resource areas since it has lower cost-per-test and is convenient. Another developing technology that has the potential to raise demand in low-resource areas is the use of AI in diagnosis. A team of researchers from the National Cancer Institute (NCI) and Global Good trained an ML algorithm to use Automated Visual Evaluation (AVE) to analyze images of a cervix and identify changes that could lead to cancer. The images can be taken with even a simple camera. New developments such as training the algorithm with a more global set of images to account for geographic variations are expected to eventually raise demand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cervical Cancer Screening is the top application for HPV testing and Pap Testing, with a CAGR of 16.7% from 2015 to 2021. The forecasted CAGR for this category is 18.4% for the period 2022 to 2032.
Neither HPV testing nor the Pap test can detect vaginal cancer on its own, but they do detect cervical cancer and pre-cancerous conditions- which are often precursors to vaginal cancer, and HPV, which increases the risk of developing vaginal cancer.
Europe is an emerging HPV Testing and Pap Test market for HPV and Pap tests. According to the European Centre for Disease Prevention and Control or the ECDC, 2.5% of all cancers in Europe are caused by HPV, and Cervical cancer is the second most common type of cancer in women of the 15 to 55 age group, after only breast cancer.
Awareness drives and official programs are driving demand. For example, in the United Kingdom, the NHS provides free tests to women every 3 years if in the 25 to 29 age category and every 5 years to women over 50 years of age. The program uses an initial HPV test and an additional Pap Test for cells that test positive.
The USA contributes significantly to the HPV and Pap Tests market, with a forecasted market size of USD 5.9 Billion by 2032. The American cancer society recommends screening with an HPV test or HPV/Pap cotest every 5 years from 25 years of age to 65 years, or a Pap Test every 3 years.
The Centers for Disease Control provides free or low-cost screenings to women who qualify based on factors like income levels and insurance coverage under their National Breast and Cervical Cancer Early Detection Program (NBCCEDP). The HPV Testing and Pap Test market in the country is expected to garner an absolute dollar opportunity of USD 5 Billion. The HPV Testing and Pap Test market in the USA witnessed a CAGR of 18.2% from 2015 to 2021 and is expected to continue growing, with a forecasted CAGR growing at 20.4%.
The HPV Testing and Pap Test market in the United Kingdom is expected to reach a valuation of USD 672.7 Million by 2032. With a projected CAGR of 20.2% from 2022 to 2032, the market is expected to garner an absolute dollar opportunity of USD 567 Million.
The HPV Testing and Pap Test market in Japan is expected to account for USD 795 Million by 2032. Growing at a CAGR of 22.4% from 2022 to 2032, the market is likely to gross an absolute dollar opportunity of USD 689 Million.
The HPV Testing and Pap Test market in South Korea is expected to reach a valuation of USD 241 Million by 2032. The market from 2022 to 2032 is expected to grow at a CAGR to garner an absolute dollar opportunity of USD 194 Million.
PAP tests are the largest contributor to HPV Testing and Pap Test market revenue, having witnessed a CAGR of 16.8% with a forecasted CAGR of 17.5% for the next decade. Their use has led to a significant decrease in Cervical Cancer deaths. However, new WHO guidelines shift to the HPV DNA-based test as preferred over the currently prevalent VIA or Pap Tests.
Despite this, Pap tests, which are the historical method in use, are still useful and common. There are concerns that additional HPV testing would mean an increase in invasive procedures. A combination of both tests is now recommended, with healthcare providers and global programs choosing whether to administer one of the two or both depending on patient age, history, and availability of resources.
HPV Testing and Pap Test providers are focused on increasing the efficiency, accuracy, and affordability of their tests and harnessing new technology. The key companies operating include Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., and bioMérieux SA
Some of the recent developments in HPV Testing and Pap Tests are as follows:
Similarly, recent developments related to companies manufacturing HPV Testing and Pap Tests have been tracked by the team at Future Market Insights, which is available in the full report.
The global HPV Testing and Pap Test market was valued at USD 2.2 Billion in 2021.
The HPV Testing and Pap Test industry is set to witness a growth rate of 19.3% over the forecast period and be valued at USD 15 Billion by 2032.
The HPV Testing and Pap Test market expanded by 17.2% from 2015 through 2021.
Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., bioMérieux SA are some of the key players in the market.
The USA, United Kingdom, China, Japan, and South Korea are expected to be the key drivers of sales.
The market in the USA accounts for over 39% of the global market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Test Type 5.1. HPV Testing 5.2. Pap Test 6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Application 6.1. Vaginal Cancer Screening 6.2. Cervical Cancer Screening 7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product Type 7.1. Instruments 7.2. Consumables 7.3. Services 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Technology 8.1. PCR (Polymerase Chain Reaction) 8.2. Immunodiagnostics 8.3. Other Technologies 9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. Asia Pacific 9.5. Middle East and Africa 10. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 11. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 12. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 13. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 14. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Abbott Laboratories 17.2. Qiagen N.V. 17.3. Becton, Dickinson, and Company 17.4. Quest Diagnostics, Inc. 17.5. Hologic, Inc. 17.6. F. Hoffmann-La Roche 17.7. Femasys, Inc. 17.8. Arbor Vita Corporation 17.9. NURX, Inc. 17.10. Seegene, Inc. 17.11. Thermo Fisher Scientific, Inc. 17.12. bioMérieux SA 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
HPV Testing and Pap Test Market
